Physician profile
David M Reich
NPI 1568541936
$2,753.82
in general payments reported to CMS, 2019-2025
24 companies · $281 in 2025
The $281 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $648 · 2020: $197 · 2021: $172 · 2022: $468 · 2023: $517 · 2024: $470 · 2025: $281.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $663.49 | 2019-2025 | Rybelsus, Ozempic |
| Abbott Laboratories | $411.08 | 2019-2025 | Freestyle Libre 3 |
| Pfizer INC. | $219.29 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $188.95 | 2019-2024 | |
| Amgen INC. | $183.14 | 2020-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $148.94 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Corcept Therapeutics | $138.06 | 2022-2025 | Korlym |
| Amryt Pharma Holdings LTD | $125.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $117.30 | 2019 | |
| Amneal Pharmaceuticals LLC | $94.54 | 2022-2024 | Unithroid |
| Insulet Corporation | $87.99 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $58.82 | 2021-2024 | Camzyos |
| Medtronic, INC. | $54.45 | 2021-2024 | Minimed 780g |
| Vifor Pharma, INC. | $40.38 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.98 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cequr Corporation | $24.09 | 2025 | Cequr Simplicity |
| Chiesi USA, INC. | $22.95 | 2025 | Mycapssa |
| Alexion Pharmaceuticals, INC. | $22.78 | 2023 | Strensiq |
| Janssen Pharmaceuticals, INC | $21.94 | 2024 | Xarelto |
| Merck Sharp & Dohme LLC | $19.60 | 2025 | |
| Xeris Pharmaceuticals, INC. | $19.32 | 2020 | |
| Vivus LLC | $19.23 | 2019 | |
| Ferring Pharmaceuticals INC. | $18.75 | 2019 | |
| Horizon Therapeutics Plc | $18.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Reich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.